Cambridge Antibody Technology, Integra LifeSciences Corp. deal

IART's Telios Pharmaceuticals Inc. subsidiary licensed to Cambridge Antibody certain rights to use anti-TGF-beta antibodies to treat fibrotic diseases. Cambridge Antibody also received right of first refusal for Telios' decorin molecule, which mediates the production of transforming growth factor-beta.

Cambridge Antibody paid $500,000 in cash at closing and is obligated to develop a dermal application for the licensed technology, which IART will market. ...